Expanded Access Program for Patients With Migraine

Study Title

Expanded Access Program for Patients With Migraine

Teva Identifier

TV48125-CNS-80005

ClinicalTrials.gov Identifier

NCT03539393

Study Status

No longer available

Trial Condition(s)

Migraine

Interventions

Drug: Fremanezumab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 70 Years

Trial Duration

01/00/1900 - 01/00/1900

Study Type

Expanded Access:Treatment IND/Protocol